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Simple Summary: Significant strides have been made to describe the pervasive role of extracellular
vesicles (EVs) in health and disease. This work provides an insightful and unifying mechanistic
understanding of EVs in immunity and tumorigenesis. This is achieved by dissecting the role
of EVs within the continuum of immune cell physiology, immune–infection responses, and the
immune–tumor microenvironment. Our work synthesizes important topical findings on immune EV
signaling in mediating immune–tumor interaction networks.
Abstract: Extracellular vesicles (EVs) are emerging as potent and intricate intercellular communication
networks. From their first discovery almost forty years ago, several studies have bolstered our
understanding of these nano-vesicular structures. EV subpopulations are now characterized by
differences in size, surface markers, cargo, and biological effects. Studies have highlighted the
importance of EVs in biology and intercellular communication, particularly during immune and
tumor interactions. These responses can be equally mediated at the proteomic and epigenomic levels
through surface markers or nucleic acid cargo signaling, respectively. Following the exponential
growth of EV studies in recent years, we herein synthesize new aspects of the emerging immune–tumor
EV-based intercellular communications. We also discuss the potential role of EVs in fundamental
immunological processes under physiological conditions, viral infections, and tumorigenic conditions.
Finally, we provide insights on the future prospects of immune–tumor EVs and suggest potential
avenues for the use of EVs in diagnostics and therapeutics.
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1. Introduction
Exosomes and microvesicles are two predominant types of phospholipid-bound extracellular
vesicles (EVs). Both are released by most eukaryotic cells into the extracellular space, albeit in differing
biogenic manners. Smaller EVs—often termed exosomes (30–150 nm) and not to be confused with the
unrelated RNA exosome complex [1]—are released via the fusion of multivesicular bodies (MVB) with
the plasma membrane. Larger EVs—often termed microvesicles (100–1000 nm)—are released by the
outward budding of plasma membrane [2]. Since the nomenclature of EVs is not well standardized in
different studies based on their biogenesis mechanisms, to avoid confusion, we will henceforth refer
to them as EVs unless specified otherwise. EV cargo in mice and humans is mainly constituted of a
combination of RNA (coding and non-coding), proteins, lipids, and possibly DNA (in specific subsets of
EVs) that generally reflect the composition of the cell of origin. Research into the intercellular signaling
mediated by EVs has revealed the possibility of distal modulation of gene expression, activation,
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and suppression of immune cells via targeted cargo exchange [3]. As a result, intercellular signaling
via EVs has been shown to elicit either positive or negative immune responses, including immune
suppression or evasion [4]. Several turning points have highlighted the importance of EVs in biology
and intercellular communication, particularly during immune and tumor responses. One of the initial
EV reports suggested that B cell EVs express major histocompatibility complex (MHC)-II and can
function as antigen-presenting bodies, therefore highlighting their potential in immunity. Subsequent
discoveries that EVs can also shuttle RNA cargo between cells, thereby eliciting phenotypic changes
in recipient cells, brought further attention to the field through their contribution to epigenomic
regulation [4]. To serve as a form of cell–cell communication, EVs carry a wide repertoire of cargo,
including proteins, RNA, and metabolites. Cells are selective and precise when sorting and packaging
cargo into EVs, often against the gradient of the cell of origin [2]. One mechanism by which EVs can
deliver such effects is through the packaging and shuttling of non-coding RNAs (ncRNAs), both small
(sncRNA) and long (lncRNA). The non-coding RNA profiles differ greatly from one donor cell to the
other, and even between EVs and their parent cells [5], indicating that packaging and shuttling EVs is a
precise and controlled process. EV ncRNAs have been shown to be powerful signaling cues that can
regulate and modulate the function of recipient cells [2].
2. The Multiple Pathways for EV Biogenesis
Several different EV biogenesis mechanisms have been elucidated thus far. However, it is not
yet clear if these can account for all EV production mechanisms, and/or if some of these mechanisms
could act redundantly together [6]. Nonetheless, these mechanisms could be broadly classified as
endosomal sorting complexes required for transport (ESCRT)-dependent or -independent, and are
further illustrated as follows.
The endocytic pathway (i.e., ESCRT-dependent) is characterized by highly dynamic membrane
compartments involved in the internalization of extracellular ligands or cellular components, their
recycling to the plasma membrane, and/or their degradation [7]. Early endosomes mature and form late
endosomes, in which intraluminal vesicles (ILVs) are accumulated in the lumen. These late endosomes
filled with multiple ILVs are generally referred to as multivesicular bodies (MVBs) and consist of
proteins, lipids, and cytosol that are specifically sorted. The more common fate of MVBs is fusion
with lysosomes that contain lysosomal hydrolases to degrade their cargo [8]. However, organelles
with MVB markers such as tetraspanins (CD9, CD63 and CD81), lysosomal-associated membrane
proteins (LAMP1 and LAMP2), and other molecules associated with late endosomes (i.e., MHC-II in
antigen-presenting cells), can also fuse with the plasma membrane, releasing their content into the
extracellular matrix [9]. The formation of MVBs and ILVs is mainly driven by the endosomal sorting
complex required for transport (ESCRT), which consists of four complexes (ESCRT-0, -I, -II and -III) with
associated proteins (VPS4, VTA1 and ALIX), conserved from yeast to mammals. The ESCRT-0 complex
binds and clusters ubiquitinated transmembrane proteins in the endosomal membrane. ESCRT-I and
-II complexes are responsible for membrane remodeling into buds and the delivery of ubiquitinated
protein cargo, and ESCRT-III components subsequently facilitate vesicle abscission. ESCRT-0 consists
of a hepatocyte growth factor–regulated tyrosine kinase substrate (HRS) that recognizes ubiquitinated
proteins and associates with the signal transducing adaptor molecule (STAM). HRS further recruits
TSG101 from the ESCRT-I complex to the endosome, and ESCRT-I is then involved in the recruitment
of ESCRT-III via ESCRT-II or ALIX. Finally, the dissociation and recycling of the ESCRT machinery is
promoted by the interaction with the AAA-ATPase VPS4 that triggers the disassembly of the ESCRT-III
complex [6].
The ESCRT-independent formation of ILVs and MVBs [10] has two variants [11]:
(i) tetraspanin-dependent EV formation, whereby tetraspanin factors such as CD63 and CD81 are
shown to be functional in the formation of ILVs (<40 nm), and sorting target receptors and intracellular
components into EVs independently of the HRS and ESCRT components [12]. Reduced secretion of EVs,
as measured by nanoparticle tracking analysis, was shown to be the result of CRISPR/Cas9 knockdown
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of CD63 in HEK293 cells [13]. (ii) Ceramide-dependent EV formation, which is independent of ESCRT
components, involves the inhibition of neutral sphingomyelinase activity (responsible for ceramide
synthesis) by GW4869. These EVs are released primarily by HEK293 cells, macrophages and other
tumor cell lines [6]. Common EV markers (CD63, CD81 or TSG101) and miRNA secretion were
decreased upon GW4869 treatment in HEK293 cells [14]. Indeed, the dependence on ceramide in EV
production was shown to vary across different cell types. GW4869 treatment in human melanoma cells
does not affect MVB biogenesis, nor EV secretion [15]. In primary cells, GW4869 treatment induces
significant cell death, leading to the unreliable analysis of EV secretion [6].
3. The Role of EVs in Immune Homeostasis
An increasing number of studies have shown that EVs are constitutively secreted by most immune
cell types, such as B and T cells, natural killer cells, dendritic cells, and macrophages. Considering the
intrinsic nature of EV biogenesis, which involves cytoplasmic endosomal sorting, it is not surprising
that immune cell-derived EVs carry proteins and nucleic acids from the cell of origin within the lumen,
as well as cell-specific antigens on the surface, reflecting their developmental status [3]. EV surface
antigens allow for the direct stimulation of recipient cells, as well as targeted homing to specific cell
types after release from parental cells. Molecular cargo is well conserved in the lipid bilayer of enclosed
EVs, allowing stable and high dimensional (i.e., RNA, DNA, protein, lipid) delivery from one cell
to another for potent gene regulation in recipient cells. Taken together, these features allow EVs to
influence host immune responses and provide an additional form of intercellular regulation, which is
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Figure 1. Extracellular vesicle (EV)-mediated immune–immune regulation. This figure depicts the
intra- and inter-cellular communications between different immune cells via the exchange or delivery
of the specific EV molecular cargo indicated and how these could exert positive or negative regulatory
effects in certain immune cells.
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3.1. The Contribution of EVs in Humoral Immunity
The activation of murine B cells via interleukin-4 (IL-4) and CD40 receptors induces a high level
release of EVs. However, CD63 (a conventional EV marker) is not detectable in murine B cell EVs,
but rather in the cell of origin [16], suggesting that CD63 is not a robust EV marker for studying
B cell-derived EVs in mice. An enriched amount of MHC-I/-II peptides, B cell receptors (BCR), and other
costimulatory molecules like CD54 and CD86 were found in both human and murine B cell-derived
EVs [3]. The B cell EV-mediated delivery of MHC-II has been shown to activate T cell immune responses
by increasing proliferation and the production of T-helper (TH)2-like cytokines [17]. Additionally, they
have also been shown to induce the cytotoxic activity of CD8+ T cells in vivo independent of host BCR
expression and circulating antibodies [18]. The localization of MHC-II from B cell EVs is also vital for
follicular dendritic cells, which are unable to synthesize MHC-II themselves to activate other immune
cells in an MHC-II-dependent manner [19,20]. The expression of adhesion molecules like ICAM-1, α4,
and β1 and β2 integrins is pronounced in B cell EVs. Integrins on EVs are functional in the context of
adhesive interactions between EVs, extracellular matrix components and other cells in the environment
during inflammation [21]. EVs derived from a Burkitt’s lymphoma cell line (DG75) induce healthy
human IgD+ primary B cells to proliferate and upregulate the expression of activation-induced cytidine
deaminase and germline transcripts for IgG1, indicating the ability of EVs to induce class-switch
recombination (CSR) and to drive B cell maturation [22–24]. Recently, B cell-derived EVs were utilized
to deliver exogenous ncRNA cargo to other immune cells in vivo. An exogenous mir-155 inhibitor
or mimic was specifically packaged into B cell EVs and shown to modulate immune responses in
macrophages and hepatocytes [25]. Whilst these are exciting developments in B cell physiology,
evidence is still lacking as to whether B cells can communicate among themselves through EVs
(Figure 1).
3.2. The Contribution of EVs in T Cell-Mediated Immunity
Activated T cells release EVs that have been shown to regulate various immunological responses
in dendritic cells, B cells, and exogenous T cells [26]. Unlike B cell EVs, conventional tetraspanin EV
markers, including CD63, are expressed more in T cell EVs than their parental cells [27]. While CD3
was readily detectable in activated CD3+ T cell EVs, no expression of MHC-I/-II peptides, CD4, CD25,
CD40 nor ICAM-1 was detected. The addition of activated CD3+ T cell EVs to resting autologous
CD3+ T cells stimulated with IL-2 displayed altered responses compared to stimulation with IL-2 alone,
resulting in increased proliferation and changes in cytokines production [28]. Human regulatory T cells
(Tregs) can produce EVs to inhibit the proliferation of effector T cells (Teffs) in a dose-dependent fashion.
This inhibition generates a switch in the cytokine profile of Teffs, with increased production of IL-4 and
IL-10 and decreased production of IL-6, IL-2 and interferon (IFN)-γ secretion [29]. Similarly, activated
CD4+ T cell-derived EVs were found to have an enriched amount of tRNA fragments (tRFs) compared
to their resting naïve state, in accordance with the fact that tRFs can inhibit T cell activation. This form of
selective tRF removal via EVs promotes T cell activation in physiological conditions [30]. Murine CD4+
T cell-derived EVs can influence B cell immune responses in vivo by enhancing proliferation, germinal
center reactions, and antibody production via transferring specific sets of miRNAs or the binding of
CD40L to CD40 [31]. Taken together, these results suggest that EVs are a new class of regulators in
T cell immunity via the delivery of sets of functionally active nucleic acids and proteins, which are
possibly responsible for modulating autoimmunity or immunodeficient diseases. However, current
EV studies are mostly based on total EV populations derived from one cell type, which are relatively
heterogeneous in terms of size, molecule expression and cargo. Thus, future studies should attempt
to study different EV subsets, as the molecular profile within each subset could be very different,
and possibly dilute the phenotypic and genotypic effect (Figure 1).
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3.3. The Contribution of Natural Killer Cell-Derived EVs
Natural killer (NK) cells also play a vital role in innate immunity by providing cytotoxicity
independently of cytokines or MHC signals. Recent studies have also shown their ability to regulate
adaptive immune responses via modulation of the immune environment [32]. EVs are released by
resting and activated NK cells, and the exosomal marker CD63 and the parental marker NKG2D are
readily detected on their surface [33]. Studies have shown that both resting and activated human
peripheral NK-derived EVs can exert cytotoxic activity on activated but not resting immune cells,
as well as on several cancer cell lines derived from T cell leukemia, erythroleukemia, Burkitt lymphoma,
and metastatic breast adenocarcinoma [32]. This suggests that EVs are one of the tools used by NK
cells to potentially increase their coverage of immune surveillance. However, the contribution of NK
cell EVs in the context of immune regulation and interaction with other immune cells is still very
understudied. Indeed, future studies on their functional roles would enhance our understanding
of EV-mediated NK cell immune regulation and could usher a new era of innate–adaptive immune
interactions via EVs.
3.4. The Contribution of EVs in the Immune Response of Antigen-Presenting Cells
Professional APCs, such as dendritic cells (DCs) and macrophages, also produce EVs to
modulate immune responses in other immune cell types. EV-specific proteins, such as ESCRT
proteins, tetraspanins, cytoskeleton proteins and heat shock proteins, are expressed readily on
DC-derived EVs [34], suggesting that related pathways might be involved in the biogenesis of DC EVs.
DC EVs also carry abundant amounts of cell type-specific markers like MHC-I and -II. Interestingly,
MHC-II molecules are stored within luminal vesicles in immature DCs. During activation, the
MHC-II-containing luminal vesicles fuse with MVBs, followed by fusion with the cell’s plasma
membrane, which subsequently increases the amount of surface MHC-II for antigen presentation [35].
Moreover, immunomodulatory mir-146a and mir-155 were found in bone marrow-derived DC (BMDC)
EVs in mice. These two miRNAs have been demonstrated to be transferred between BMDCs, with
EV-delivered mir-146a suppressing inflammatory responses to lipopolysaccharide (LPS) in recipient
wild type (WT) mice. However, mir-155 transferred between BMDCs via EVs promoted inflammatory
responses to LPS in recipient mir-155 knockout mice [36], suggesting that EVs can exert both positive
and negative effects on host immunity. If the enrichment of mir-146a or mir-155 occurs in different
EV subpopulations, one could purify certain EV subpopulations from the same parental cells to serve
different biological and clinical purposes. Macrophage-derived EVs also express tetraspanins and
heat shock proteins similarly to other cell types, although the expression levels are not significantly
enriched compared to cell lysates. EVs released from pathogen-infected (mycobacteria, salmonella,
or toxoplasma) macrophages carry MHC-I and -II, as well as costimulatory molecules such as CD86
that are able to activate CD4+ and CD8+ T cell responses both in vitro and in vivo [37]. Overall,
EVs are becoming a novel and legitimate class of intercellular signaling players between immune
cells to orchestrate immune responses in physiological conditions, pathogenic infections, and cancer
development in mammalian systems. However, the field of EV studies is still in early development.
The identification and functional studies of significant EV cargo in different immune contexts are
contributing multidimensionally to the field by filling some missing gaps in certain known pathways.
Combining this knowledge and introducing this new viewpoint for studying immune regulation
will provide novel mechanisms that could be strategically implemented into clinical diagnostics
and therapeutics.
4. The Emerging Role of EVs in Viral–Immune Interactions
Host–pathogen interactions can drastically affect immune signaling [38]. This is most obvious with
viruses, which are obligate intracellular pathogens. Under these conditions, EVs have been shown to:
(i) act as viral decoys for immune recognition [39]; (ii) increase the breadth of viral virulence [40,41]; and
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(iii) potentially increase viral tropism [42,43] (Figure 2). A fourth hypothetical scenario we propose here
is the potential for viral EVs to act as pseudo-morphogen gradients for both immune and non-immune
cell recruitment. While EVs have been suggested to create a pseudo-morphogen gradient in the past, it
remains to be shown whether viral EVs could mediate a similar response (Figure 2).
Infected cell
Viral infectionPositive decoy























Figure 2. Extracellular vesicle-mediated immune–viral regulation during infection. This figure depicts
the potential mechanisms by which virus-encoding EVs could alter virus–host interactions mediated
by specific viral EV molecular cargo as indicated. These include the regulation of immune evasion,
viral tropism, viral virulence, and potentially immune cell recruitment.
It has been shown that viruses are able to induce EV secretion in infected cells, and these EVs
can mediate the spread of different viruses. One example is Coxsackievirus B1, which through the
depolymerization of the actin cytoskeleton of the infected cell, induces the release of EVs and enables
virus spread [44]. Other non-enveloped viruses, such as picornaviruses and enteroviruses, have been
described to use EVs to spread in the host [45,46]. Surprisingly, this is also true for infection between
species. Indeed, it was recently reported that the transmission of Langat virus from arthropods to
humans is mediated by EVs that are secreted by ticks, which deliver viral RNA and proteins to human
keratinocytes [47]. At the same time, EV-mediated communication is also used by the host as a defense
mechanism against viral infection, activating the immune response in non-infected cells. The role
of EVs in viral infection has been characterized for human immunodeficiency virus type 1 (HIV)
and the Epstein–Barr virus (EBV). In HIV, EVs can both positively and negatively promote tumor
spread [48,49]. For example, CD4 has been shown to be essential for HIV entry to specific cell types
such as M1 macrophages and fibroblasts, and it was recently shown that T cell EVs expressing CD4 on
their surface could act as a positive decoy for the virus, thereby acting as bait to recruit the virus away
from the cells and avoid cell infection [39,49]. At the same time, CD8+ T cell-derived EVs express
surface factors that have proven antiviral activity. On the other hand, EVs have been shown to enhance
HIV infection through several mechanisms. An example of this is the EV-based transfer of CCR5 and
CXCR4 receptors to other cells, rendering them susceptible to HIV entry [50,51]. Additionally, EVs
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can also transfer viral proteins such as Env, Gag, and Nef that could help viral spread and promote
immunodeficiency [52]. As supporting evidence of the central role of EVs in HIV infection, it has been
shown that plasma from HIV patients contains higher levels of EVs and that these EVs contain more
pro-inflammatory cargo [53,54] (Figure 2).
Numerous recent studies have shown that Esptein–Barr virus (EBV), a human gamma herpesvirus
associated with lymphoproliferative disorders such as Burkitt lymphoma (BL) and diffuse large B-cell
lymphoma (DLBCL), utilizes EVs as a signaling tool to facilitate viral transmission via modulation of
host immune defense [55]. During DLBCL formation in a humanized mouse model, EVs derived from
EBV transformed lymphoblastoid cell lines (LCLs) and switched macrophages to a proinflammatory
state via the delivery of EBV miRNAs. Strikingly, the injection of EVs derived from one of the
LCL EBV+ strains significantly reduced the survival rate of the mice [43]. EVs derived from LCLs
have also been shown to be taken up by DCs, where the EBV miRNA is delivered. This transfer of
EBV miRNA from LCLs to DCs led to the repression of CXCL11 (an immunoregulatory EBV target
gene) reporter expression in recipient DCs [56]. Latent membrane protein 1 (LMP1), an EBV specific
protein, has been shown to be expressed on the surface of EBV-infected cell-derived EVs. LMP1 on
these EVs possibly inhibits T cell proliferation and NK cell toxicity [22,57]. EBV-infected cell-derived
EVs also express galectin-9, which induces the apoptosis of EBV-specific CD4+ T cells through an
interaction with T cell immunoglobulins [57]. A paracrine loop of EBV lytic replication enhancement
has recently been shown to be an EV-mediated process. EBV-infected B cells secrete EBV-encoded
non-coding RNA-containing EVs to neighboring infected B cells, where the EVs increase CXCL8
expression via endosomal Toll-like receptor (TLR) 7, ultimately promoting lytic replication, which is
vital for viral propagation [42]. Taken together, EVs are used by viruses as a novel tool to promote their
propagation through modifications to immune responses in the host, thus increasing viral tropism.
However, compared to professional APCs, little is known about the interactions between EBV-infected
cell-derived EVs and non-infected lymphocytes. One study has shown the presence of EBV miRNAs
in non-infected human peripheral B cells, suggesting the possibility of EV-mediated EV transfer from
EBV infected cells to other B cells (Figure 2).
5. EV-Mediated Crosstalk in Immune–Tumor Cell Interactions
Rapidly cell division represents only one factor in the complex process of tumorigenesis.
Tumor surroundings are composed of a dynamic network of non-malignant cells, non-cellular
components, signaling molecules, and extracellular matrices (ECM) [58–60] which collectively form the
tumor microenvironment (TME). The TME is involved in a bi-directional interaction with the tumor
mass to sustain and contribute to the growth and spread of the tumor [60]. Such communication
is underlined in an increasing body of evidence that highlights the key role played by the TME
in tumor progression [59,61–63]. In addition, many studies have reported the positive role of the
TME in restraining tumor initiation and progression at initial stages of carcinogenesis [64], and how
“re-programming” the TME in later stages holds great potential in terms of effective cancer treatment [59]
(Figure 3).






Figure 3. Extracellular vesicle-mediated tumor microenvironment (TME) communication. Schematic
depiction of interactions in the TME between the tumor and surrounding cells promoting
immune-suppression, angiogenesis, metastasis, and therapy-resistance. Factors and EVs in blue
denote uptake-dependent processes; factors and EVs in grey denote uptake-independent processes.
5.1. Tumor–Tumor Interactions via EVs
Cancer cells communicate with each other to sustain the growth and survival of the tumor in
a hostile microenvironment. The release and uptake of EVs containing signaling cargo is one form
of cell–cell communication used by cancer cells. EVs have been implicated in cancer progression
by promoting proliferation, angiogenesis, and immune suppression. Within the primary tumor
itself, autocrine signaling, mediated through the shuttling of EVs, promotes a more transformed
phenotype in the recipient cells. In glioma cells, EVs were shown to shuttle oncogenic proteins to
recipient cells, therefore leading to altered signaling and proliferation despite the lack of genomic
alterations. For example, the transfer of epidermal growth factor receptor (EGFR) variant III (EGFRvIII)
from expressing glioma cells to non-expressing cells aided their transformation and enhanced cancer
growth [65]. Similarly, EVs have been shown to promote cancer proliferation and progression in
chronic myeloid leukemia [66], brain [67,68], gastric [69,70], and bladder [71] cancers. Cancer autocrine
signaling via EVs is also involved in other pro-tumor processes, including conferring drug resistance
in sensitive cells, which will be discussed in more detail in the following sections.
5.2. Tumor–Immune TME Interactions via EVs
One critical component of the TME are immune cells, which are involved in a cross-talk with the
tumor via several secreted proteins and EVs. Cancer cells are able to recruit immune cells to promote
the growth and survival of the tumor (Figure 3).
The important role of T cells in antitumor immunity is well established, as they are considered the
major contributor to antitumor immunity, being the most common tumor-infiltrating lymphocytes
in the tumor vicinity. Studies have reported on the immune suppressive effects of cancer-derived
EVs on T cells, either by inhibiting their proliferation [72], inducing apoptosis [73], or diminishing
their cytotoxic ability [74]. For instance, melanoma EVs are shown to target CD4+ T cells to promote
the growth of the tumor by inducing caspase-mediated apoptosis once up taken by T cells [75].
These findings are consistent with data showing that melanoma-derived EVs isolated from plasma
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significantly induce apoptosis and inhibit proliferation in CD8+ T cells [76]. Similarly, EVs of breast,
lung, and nasopharyngeal carcinomas have been implicated in targeting T cells by inhibiting their
proliferation and blocking their differentiation and activation [77,78]. Moreover, melanoma cell
line-derived EVs were shown to influence the epigenetic landscape of recipient cytotoxic T cells via the
delivery of a subset of non-coding and coding RNAs. This supports the the potential of EVs as a new
class of epigentic regulator [79].
B cells are central to humoral responses and antitumor immunity. In addition to producing
antibodies against a limitless array of targets, B cells are able to shape the functions of other immune
cells by antigen presentation, co-stimulation, and cytokine secretion [80–82]. Indeed, tumor-infiltrating
B cells have been reported to be involved in different stages of carcinogenesis, shaping the immune
response according to microenvironmental cues [82,83]. For example, mycoplasma-infected melanoma
cells release EVs that selectively activate B cells to secrete IL-10, leading to the inhibition of T cell
proliferation and activity [84]. Restricting the exposure of B cells to melanoma-derived EVs by
CD169+ macrophages has been shown to block tumor-promoting humoral immunity and suppress
tumor growth [85]. Similarly, B cells exert an immunosuppressive effect in response to esophageal
cancer-derived EVs. Naïve B cells differentiate into regulatory B cells after exposure to esophageal
cancer-derived EVs, where they produce TGF-β, leading to CD8+ T cell inhibition [86].
Another major contributor in the immune TME are NK cells, which participate in
immunosurveillance and tumor suppression. Several studies have reported on the role of NK
cell-derived EVs in different cancers, and their antitumor effects in vitro and in vivo, even under
immunosuppressive conditions [87,88]. It has been shown that NK cell-derived EVs can activate
different cell death pathways in cancer cells, including endoplasmic reticulum ER stress-induced
apoptosis, and caspase-dependent and -independent pathways [89]. NK cell-derived EVs display the
DNAM1 receptor on their surface, which enhances their binding and induces cytotoxicity towards
target cancer cells [90]. The cytotoxic activity of NK cell-derived EVs has also been shown to be exerted
at low concentrations and after a short time exposure [90]. This observation is consistent with the
activating role of DNAM1 in the anti-tumor response of NK cells [91,92], where it also plays a key role
in immunosurveillance [93–96] and the suppression of metastasis [97].
In addition, NK cell-derived EVs have been shown to shuttle certain miRNAs that induce an
anti-tumor response even in immunosuppressive TMEs [98], where they can exert cytotoxic effects
specifically against tumor cells [32]. Indeed, the newly studied miR-3607-3p is found to be enriched in
the EVs of NK cells as a way to deliver them to pancreatic cancer cells [99]. NK cell- and EV-derived
miR-3607-3p inhibited the proliferation, migration and invasion of pancreatic cancer cells through
the inhibition of IL-26 [99]. These findings are consistent with the suppressive role of miR-3607-3p
that has been reported in non-small cell lung cancer (NSCLC), where it has been shown to induce cell
cycle arrest and inhibit tumor growth and metastasis [100]. Interestingly, miR-3607-3p has also been
reported to be downregulated in both NSCLC and pancreatic cancer tissues, and its expression can
be used as a prognostic predictor for survival [99,100]. In neuroblastoma, NK cell- and EV-derived
miR-186 plays a similar role in suppressing cancer cell growth and preventing TGFβ1-dependent
immune escape [89]. miR-186 has further been shown to regulate many processes in different human
cancers, and to be a marker for diagnosis and prognosis [101].
On the other hand, tumor cells can release EVs to limit the cytotoxic capacity of NK cells.
Co-culturing NK cells with immunosuppressive pancreatic cancer-derived EVs expressing TGF-β1
resulted in the significant downregulation of NKG2D, CD107a, TNF-α, and INF-γ in NK cells, reducing
their cytotoxicity against pancreatic tumors [102]. Similarly, membrane-associated TGF-β1 present
on EVs derived from the sera of acute myeloid leukemia patients inhibited natural killer cell activity
and downregulated NKG2D [103]. Also, hypoxic tumor-derived EVs have been shown to inhibit NK
cell cytotoxicity in vitro and in vivo through shuttling of TGF-β and miR23a [74,104]. In addition,
treatment with tumor-derived EVs decreased NK cell percentage in lungs and spleens in a murine
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mammary carcinoma model. EVs derived from mammary carcinoma suppress NK cell function in vitro
and ex vivo [101].
5.3. Tumor–Stroma Interactions via EVs
The tumor stroma has been shown to be involved in the process of tumorgenesis in early
stages by providing either a supportive or inhibitive “soil” for growth. The components of the
stroma (i.e., fibroblasts, mesenchymal stem cells, and the ECM) have been shown to uptake cancer
derived-EVs and secrete EVs containing miRNA/lncRNA/protein cargo to enhance tumor growth
and survival. Mesenchymal stem cell (MSC)-derived EVs promoted tumor growth in different
cancers both in vivo and in vitro via inducing VEGF overexpression and the activation of the ERK1/2
pathway [105]. In breast cancer, MSC-derived EVs were shown to secrete mir-222/223-containing
exosomes to stimulate cancer cell quiescence, and subsequently drug resistance [106]. Similarly,
MSC-derived EVs increased the expression of multidrug resistance-associated protein (MDR) proteins
and activated CaM-Ks/Raf/MEK/ERK pathways to promote drug resistance in gastric cancer cells [107].
Fibroblast-derived EVs promoted the growth and metastasis of colorectal cancer in both in vitro and
in vivo models [108], and promoted a more aggressive phenotype in breast and pancreatic cancer
cells [109,110]. Fibroblast-derived exosomal miR-21, -106b, -98, and -522 have been implicated in
driving drug resistance in ovarian, gastric, and pancreatic cancers [111–114]. Stromal-derived EVs also
play a role in other hallmarks of cancer drivers including migration and metastasis [115–118].
5.4. Cancer Stem Cell Signaling via EVs
Cancer stem cells (CSCs) are key players in the tumor microenvironment, where they have been
highlighted as major contributors to drug resistance. CSCs and other cancer cells are in a continuous
state of equilibrium where non-CSCs can de-differentiate into CSCs, and vice versa. Several studies
have implicated exosomes as carriers of de-differentiation cues. Exosomal-mediated Wnt signaling has
been shown to drive the de-differentiation of cancer cells to obtain stem-like properties and phenotypes
in diffuse large B-cell lymphoma [119] and colorectal cancer [120,121]. Stroma-derived exosomes
shuttling IL-6 and activin-A were shown to de-differentiate lung cancer cells into CSCs, and promote
the activation of stemness-promoting pathways including the Wnt pathway [122]. Colorectal cancer
stem cell-derived exosomes promoted stem-like properties and phenotype in colon cancer cells via
miR-146a, in addition to enhancing their tumorigenic and immunosuppressive abilities [123].
6. Mechanisms of Immune–Tumor Cell Communications
EVs have been implicated in cancer progression by promoting proliferation, angiogenesis,
and immune suppression [124]. Immune cells are recruited to the tumor vicinity as a response
to TME cues, an example of which is EV-mediated signaling, whether it be immune-activating or
immune-suppressing (Figure 3).
6.1. Uptake-Dependent Communication via sncRNA
Cancer cell- and EV-derived miRNAs have been implicated in several cancer-promoting pathways.
Many studies have shown the role of EV miRNAs in promoting angiogenesis, a key hallmark of cancer
progression, in several cancers. For example, colorectal cancer cells package miR-1229 into their EVs to
target the HIPK2/VEGF pathway, promoting angiogenesis in vitro and in vivo [125]. Treatment with
an antagomir against miR-1229 impaired tubulogenesis of HUVECs and inhibited tumor growth
and angiogenesis in xenograft models [125]. Moreover, miR-210 has been implicated in promoting
angiogenesis and enhancing tube formation in endothelial cells co-cultured with hypoxic leukemia cell
EVs [126]. In addition, miR-210 has been shown to promote angiogenesis in lung adenocarcinoma and
hepatocellular carcinoma (HCC). Overexpressing TIMP-1 led to the upregulation of miR-210 in lung
adenocarcinoma-derived EVs in vitro and in vivo, subsequently leading to enhanced tube formation in
HUVECs and increased angiogenesis in xenograft models [127]. Similarly, HCC cells package miR-210
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in their EVs to promote tubulogenesis in vitro and enhance angiogenesis in xenograft models via the
SMAD4 and STAT6 pathways [128].
EVs are also excellent mediators of metastasis as they can exert their effects in local or remote
microenvironments, as well as in an organ-specific manner [129]. EV-based communication has been
implicated in preparing a hospitable pre-metastatic niche and promoting tumor spread in several
cancers by different means, such as localizing in common sites of metastasis and increasing endothelial
permeability [130], helping in the formation of a pro-inflammatory niche [131], and destroying the
blood–brain barrier to promote brain metastasis [132].
It has become clear that tumors can transmit pro-metastatic cues to their TME via miRNA packaged
in their EVs. In triple-negative breast cancer cells, miR-939 and miR-105 are packaged in EVs, where
they target vascular endothelial cadherin (VE-cadherin) and Zonula occludens-1 (ZO-1), respectively,
once up taken by endothelial cells, resulting in the disruption of the endothelial barrier and increased
permeability [133,134]. Exosomal miR-103 plays a similar and critical role in the metastatic process of
HCC via directly targeting multiple endothelial junction proteins of endothelial cells, thus increasing
vascular permeability and allowing metastatic formation [135].
Multiple studies have reported on the role that miR-10b plays in metastasis formation. It has
been implicated in the progression of 18 cancer types including, but not limited to, breast, brain,
and gastrointestinal tumors [136]. More recently, studies have directed their focus on the part that
EVs play in miR-10b-mediated metastasis formation. In HCC, miR-10b promotes migration, invasion,
and tumor spreading via the inhibition of CADM1 [137,138], a suppressor of invasion and survival,
and through modulating matrix metallopeptidases expression [123], which are key participants in
ECM remodeling and metastasis. Notably, the overexpression of miR-10b from HCC patient sera EVs
can even be associated with poor disease-free survival [139]. These findings are consistent with others
showing a considerable increase in miR-10b in HCC EVs, leading to enhanced proliferation, migration,
and invasion in vivo and in vitro [140]. miR-10b level was elevated in EVs derived from the sera of
early HCC patients, where it was linked to advanced tumor stage and an independent prognostic
factor for early HCC patient disease-free survival (Figure 3).
Interestingly, cancer- and EV-derived miRNAs can also promote the metastatic process
indirectly through “reprogramming” of the TME to become complicit in driving tumor spread.
Exosomal miR-10b secreted by CRC cells modulates fibroblasts in the surrounding stroma via
suppression of PIK3CA expression and downregulation of the PI3K/Akt pathway [141]. Once taken up
by fibroblasts, EVs containing miR-10b transform the cells into cancer-associated fibroblasts expressing
myofibroblastic markers that are capable of promoting CRC growth in vitro and in vivo. A similar
“reprogramming” of fibroblasts to promote the invasion and formation of a pre-metastatic niche
has been reported in triple-negative breast cancer and melanoma via EV-derived miR-9 [142] and
miR-155/miR-210 [143], respectively.
6.2. Uptake-Dependent Communication via lncRNA
EVs are also known to package other lncRNAs to exert a response in recipient cells. EV-derived
lncRNAs have been implicated in many aspects of cancer progression. In NSCLC patients,
metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) has been shown to be highly
expressed in the serum, and that the level of exosomal MALAT-1 correlates with tumor stage and
metastasis status [144]. Moreover, exosomal MALAT-1 seemed to play a supporting role in migration
and proliferation. Another lncRNA involved in EV-mediated metastatic spread is Hox antisense
intergenic RNA (HOTAIR). HOTAIR has been shown to be packaged in EVs from laryngeal squamous
cell carcinoma [145] and urothelial bladder cancer [146] cells, promoting metastasis formation and
correlating with clinical stage. EV-derived HOTAIR has also been shown to play a role in angiogenesis in
neuroblastoma, where glioma cells shuttle it to endothelial cells to induce Vascular Endothelial Growth
Factor A (VEGFA) expression [147] and silencing of HOTAIR-inhibited glioma-induced endothelial cell
proliferation, migration, and tube formation [147]. EV-based lncRNA is also implicated in promoting
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therapy resistance. For instance, the high expression of urothelial cancer associated 1 (UCA1) in breast
cancer EVs correlates with tamoxifen resistance [148]. In renal cell carcinoma, sunitinib-resistant cells
highly express lncARSR, which in turn is packaged in RCC EVs to be shuttled to recipient cells [149].
6.3. Uptake-Independent Communication
Most studies have shown that EV-mediated communication is cargo uptake dependent, in which
EVs release their cargo after being taken up by recipient cells. However, there is emerging evidence
that shows the ability of EVs to deliver signals independent of uptake via surface proteins. Displaying
proteins on the surface of their EVs allows cancer cells to exert immunosuppression systemically.
Malignant ascites from ovarian cancer patients release soluble E-cadherin on the surface of EVs,
promoting angiogenesis via the activation of β-catenin and NFκB signaling in endothelial cells [150].
Similarly, EVs derived from ovarian, colorectal, and renal cancer cells express the 189 amino acid
VEGF isoform on their surface [151]. VEGF189 EVs were shown to promote endothelial cell migration
and tube formation, in addition to angiogenesis and xenograft tumor growth, independently of
uptake. Interestingly, the VEGF189 isoform was more favorably localized to cancer-derived EVs than
other isoforms of VEGF via high affinity binding to heparin, increasing its half-life and impairing its
recognition by the VEGF antibody bevacizumab.
6.4. EV-Mediated Tumor Resistance to Immunotherapy
EVs have emerged as a potent mode of drug/therapy resistance in cancer, where they have been
shown to enhance resistance in aggressive cancers and even to transfer resistance to cancer cells that
were once sensitive to treatment. One way in which resistant cancer cells counter treatment is through
encapsulating anti-cancer agents into EVs and expelling them into the extracellular environment,
which has been reported in several cancers. Indeed, breast cancer cells have been shown to package
doxorubicin in their EVs to eject it outside the cell [152]. Similarly, a number of studies reported that
melanoma [153], ovarian [154], and lung cancer cells [155] encapsulate cisplatin in their secreted EVs to
eject it into the extracellular environment. Interestingly, glioblastoma EVs are enriched in autologous
neoantigens that are capable of inducing DC-mediated anti-tumor immune responses [156], thus
revealing a new class of cell-free presentation of neoantigens for anti-tumor immunity.
Melanoma immunotherapy resistance depends on the overexpression of PD-L1, and it has been
recently shown that the majority of melanoma PD-L1 is shuttled through EVs and not displayed on
the cell surface [157–159]. EV-derived PD-L1 has been shown to elicit immunosuppressive effects
similar to cellular PD-L1, which promotes immune evasion in melanoma tumors by inhibiting CD8+
T cell responses [160], where the blockade of PD-L1 induces systemic anti-tumor immunity [157,158].
Similarly, aggressive B cell lymphomas are able to evade immunotherapy targeting CD20, such as
rituximab, by releasing EVs with CD20 on their surface to shuttle the antibodies away from the
lymphoma cells [161].
EVs can also transmit resistance by transferring bioactive cargo such as proteins, miRNAs,
and lncRNAs from resistant to sensitive cancer cells. For example, EVs are thought to confer drug
resistance in osteosarcoma [162], where cancer cells with multi-drug resistance (MDR) transferred
the drug resistance phenotype to sensitive cells in vitro by packaging MDR proteins into their EVs.
This allows recipient cells to expel uptaken drugs and to stop the accumulation of anti-cancer drugs
inside the cell. Similar findings have been reported in acute T lymphoblastic leukemia [163] and
prostate [164] and ovarian [165] cancers. Moreover, EV-transferred resistance via P-glycoprotein 1
(P-gp1) could be permanent, or at least prolonged, both in vitro and in vivo in many tumor types [166].
This observation could be partially explained by the EV-derived miRNA-mediated regulation of P-gp
expression by miR-27a and miR-451 [167,168]. EV-packaged miRNAs have also been shown to promote
resistance through modulating the expression of different genes. In breast cancer cells, miR-222, -221,
-100, -30a, -17, -23a, and -149 were shown to be taken up into drug-sensitive cells via EVs derived from
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resistant cells, which promoted resistance against a number of drugs including docetaxel, tamoxifen,
and adriamycin [169–172].
7. Future Therapeutic Perspectives for EVs
The ability of EVs to mediate intercellular communication and modulate target cell behavior
has several potential therapeutic applications. EVs have been proven to be optimal targets for early
detection in liquid biopsy of several cancer entities [173]. Due to technical limitations of the current
cytometers, as well as the heterogenity of EVs derived from patients, the implementation of successful
EV-based diagnosis has been delayed. Innovative technologies for EV studies have emerged in the
past few years, such as super-resolution microscopy and multiplex imaging cytometry. However,
the rather low throughput and tedious sample preparation of these technologies are still significant
barriers for robust basic and clinical EV research. Recent developments in nanosize particle-specialized
cytometers and optimized materials for calibration beads are set to overcome the issues of sensitivity
and unspecificity in current instruments [173]. This advancement will ultimately allow for the
reproducible measurement of single EV particles and their surface markers in a high throughput
manner. To tackle the inconsistency and reproducibility from one study to another, Minimal Information
for Studies of Extracellular Vesicles 2018 guidelines shall be implemented in EV-related studies in
the conetext of nomenclature, processing, separation, characterization, and functional studies of
sample EVs. Combined with the ability to sort individual particles and next-generation sequencing,
these technologies could open a whole new era for both EV characterization and EV-based diagnosis.
Additionally, it has been recently proven that proteomic profiling of EVs can provide novel ways for
the prediction of treatment responses, the classification of tumors of unknown origin, and the early
detection of tumors [174].
The ability of EVs to mediate intercellular communication and modulate target cell behavior has
several potential therapeutic applications. EVs derived from several immune cells, such as DCs and NK
cells, have been efficiently tested as potent anti-tumor therapies [175,176]. A striking recent example
is the use of CAR T cell-derived EVs as a therapeutic alternative to CAR T therapy. Indeed, it was
shown that EVs derived from CAR T cells were able to exert antitumor activity and show higher safety
than CAR T cell therapy itself [177]. Recently, a group showed that B cell-derived EVs reduce T cell
activation in response to chemotherapy, and therefore inhibiting B cell EV secretion could increase
chemotherapy efficacy [178]. The discovery of autologous neoantigens in cancer EVs reveals a high
potential for EV-based neoantigen vaccines and therapeutics, without the manipulation of host cells
that could trigger unexpected responses. In addition, EVs release inhibitors that have been studied and
tested in pharmacological applications [179]. The up-to-date mechanisms and range of EV inhibitors
are still rather unspecific and unable to cover all types of EV release. Future work aimed to selectively
block the release of detrimental EVs without affecting the ones with physiological roles will allow for
new therapeutic approaches to suppress cancer growth and spread. EVs have also been proposed
as flexible cargo for therapy delivery, showing great ability to be manipulated and exert the desired
effect [180]. Considering all this evidence, EVs are emerging as a potent and flexible therapeutic
tool that could be implemented for the diagnosis and treatment of several diseases. Technological
development in the coming years will allow us to fully exploit their benefit for early diagnosis and as
novel therapeutic options to be used alone or in combination with standard clinical regimens.
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